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 Abstract 
 
Haematological malignancies are a diverse group of cancers that affect the blood, 
bone marrow and lymphatic systems. Laboratory diagnosis of haematological 
malignancies is dependent on combining several technologies, including 
morphology, immunophenotyping, cytogenetics and molecular genetics correlated 
clinical details and classification according to the current WHO guidelines. The 
concept of the Specialised Integrated Haematological Malignancy Diagnostic 
Services (SIHMDS) has evolved since UK NICE Improving Outcomes Guidance 
(IOG) in 2003 and subsequently various models of delivery have been established. 
As part of the 2016 update to the NICE IOG, these models were systematically 
evaluated and recommendations produced to form the basis for quality standards for 
future development of SIHMDS. We provide a summary of the systematic review and 
recommendations. Although the recommendations pertain to the UK NHS, they have 
relevance to the modern delivery of diagnostic services internationally. 
Definitions  
Local reporting: service models in which haematological cancer diagnosis is made within a local laboratory of an 
associated clinical department. 
Co-located: service models in which haematological cancer diagnosis is provided in dedicated, purpose-built and 
localised laboratories. 
Networked: service models in which established laboratories work on the same information network, but are 
geographically separate and not dedicated solely to haematological cancer diagnosis. 
Integrated report: A single report summarising all elements of laboratory diagnosis for a specific patient episode 
i.e. based on available haematological cytology, histopathology, immunophenotyping by flow cytometry, 
cytogenetics, FISH and molecular genetics and in accordance with the current WHO diagnostic classification. 
Integration: The process of producing an integrated report. 
  
Introduction 
National Institute for Health and Care Excellence (NICE) service guidance is based 
on the best available evidence of clinical and cost effectiveness, and is produced to 
help commissioners, NHS Trusts, managers, healthcare professionals and patients 
make informed choices about appropriate healthcare to improve the effectiveness 
and efficiency of healthcare services.  
 
Haematological malignancies include leukaemias, lymphomas and myeloma and 
originate mainly in the bone marrow and lymph nodes. They are a diverse group of 
diseases affecting people of all ages, but with highest incidence among the elderly. 
Prognosis and responsiveness to treatment of these conditions also varies widely.  
Haematological malignancies accounted for 8.4% of all malignant disease (excluding 
non-melanoma skin cancer) diagnosed in England in the years 2001 to 20101 
 
Accurate diagnosis of haematological malignancies involves haematological and 
histopathological cytomorphology, immunophenotyping by flow cytometry and/or 
immunohistochemistry, cytogenetics and molecular genetics, including cutting edge 
technologies, such as next generation sequencing (NGS). Clinical information is also 
essential, both at the time of specimen analysis and when discussing diagnostic 
reports in a multidisciplinary team meeting.  This approach is built into the World 
Health Organisation (WHO) classification for all haematological malignancies and 
updates of this classification2-4 provide a diagnostic framework that emphasises the 
importance of integrating all these modern diagnostic tests. 
 
Historical evidence, based principally on lymphoma, supports between 5% and 15% 
of haematological malignancies being misdiagnosed, sometimes with major clinical 
consequences5-7.  Such errors can be difficult to detect after a patient has been 
treated and so it is very important that the initial diagnosis is correct and supported 
by strong evidence from several independent investigative modalities.  
 
In the United Kingdom (UK) the 2003 NICE Improving Outcomes Guidance (IOG) for 
Haematological Malignancies emphasised the importance of an integrated diagnostic 
approach to haematological malignancies8. The original guidance defined two levels 
of haematological malignancy diagnostic service - a local service, which provides 
initial assessment of specimens and a specialist laboratory service.  A specialist 
service uses predefined diagnostic pathways to analyse specimens using a variety of 
diagnostic modalities, then validates and correlates the results to produce an 
integrated diagnostic report. This approach has been gradually adopted across the 
country and the specialist laboratories are now known as Specialist Integrated 
Haematological Malignancy Diagnostic Services (SIHMDS).  
 
Despite the 2003 NICE IOG for Haematological Malignancy recommendations that 
all diagnostic technologies should be provided by D VLQJOH ODERUDWRU\ µFR-ORFDWHG¶
services), the adoption of a single co-located SIHMDS structure has been variable 
across England with little progress beyond local reporting by separate laboratories in 
some regions. 
 
In 2016 the IOG was revised and included an economic appraisal of SIHMDS as well 
as additional guidance relating to these laboratories1. The original IOG was limited to 
adult patients (age 16 years or more) despite a similar requirement for integrated 
diagnostic technologies in the diagnosis of haematological cancers in childhood in 
accordance with the WHO classification. The updated NICE IOG applies to all ages. 
 
The aim of this best practice review is to summarise the evidence and 
recommendations for SIHMDS laboratories included in the revised IOG for 
Haematological Malignancies. Although the NICE guidance will be most relevant to 
SIHMDS in England, the general principles will be relevant to specialised laboratory 
practitioners and healthcare providers who work in the field of cancer internationally. 
Methods: Evidence review during NICE Improving Outcomes Guidance 
development in relation to SIHMDS  
a) Service configuration 
Most of the published research on cancer topics focuses on clinical evaluations of 
treatment; little direct research has been carried out on the organisation and delivery 
of services. 
 
b) Epidemiology  
This was key to the review in order to understand the routes through which patients 
with haematological malignancies might present initially or at relapse to healthcare 
services, to inform the shape of these services.  
 
Accurate capture of information on haematological malignancies nationally, despite 
recent improvements, is still challenging. Haematological malignancies are diverse, 
ranging from highly aggressive types to incidentally identified indolent conditions.  
Certain chronic leukaemias rarely produce symptoms, and the recorded incidence of 
these conditions depends on whether blood samples are examined and on the 
criteria used for deciding whether there is a malignancy.  Even when it is clear that 
there is a malignancy, identifying the specific type requires sophisticated diagnostic 
techniques and the integration of information from clinical and laboratory sources. 
These results are not always available to the Cancer Registries and so some 
registrations fail to capture the precise diagnosis. This is particularly true of non-
Hodgkin lymphoma (NHL), a large and varied group of conditions, for which the ICD-
10 coding may be inadequately detailed to separate distinct entities or present other 
challenges for accurate classification in routine practice.  
 
Data sources for the guideline included the National Cancer Registration Service 
(NCRS), which is part of Public Health England (PHE), the National Cancer 
Intelligence Network (NCIN), the Office for National Statistics (ONS), the Patient 
Experience Survey, National Audit of Cancer Diagnosis in Primary Care, Hospital 
Episode Statistics (HES), National Cancer Data Repository (NCDR) and regional 
data taken from the Haematological Malignancies Research Network (HMRN). 
 
Population-based national incidence rates for England (as estimated by cancer 
registrations) rose over the period 2001-2010 for some haematological cancers: 
Hodgkin lymphoma, non-Hodgkin lymphoma (NHL) and myeloma. There are no 
haematological cancers for which incidence rates declined over that period. 
Registration rates for haematological cancers may have changed because of better 
ascertainment of new cases and developments in both diagnosis and classification; 
therefore the changes seen may not represent true changes in incidence1.  
 
Relative survival improved for individuals in specific age groups who were diagnosed 
between 2000 and 2010 for a number of haematological cancers: acute 
lymphoblastic leukaemia (0-14 years males and females; 15-64 years males), acute 
myeloid leukaemia (15-64 years), chronic myeloid leukaemia, non-Hodgkin 
lymphoma, and myeloma. For the most common forms of leukaemia in older people 
(adults aged 65 years or more), namely acute myeloid leukaemia and chronic 
lymphocytic leukaemia, there was no evidence of significant change in the outcome 
for patients over this time period1. 
 
The incidence of haematological malignancy does not generally vary between areas 
with different levels of deprivation, apart from acute myeloid leukaemia (AML) and 
Hodgkin lymphoma. Deprivation was also associated with poorer relative survival for 
chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), Hodgkin 
lymphoma, myeloma and NHL1. 
 
For the majority of haematological malignancies, GP referral was the most common 
route to diagnosis, with the exception of AML and ALL, in which over half of all 
patients presented to hospital as an emergency. CML and myeloma had similar 
proportions of GP referral and emergency presentations. All haematological 
malignancies with the exception of Hodgkin lymphoma had a significantly higher 
proportion of emergency presentations than malignancies in general. Relative 
survival was significantly poorer for emergency presentations for most 
haematological malignancies. The exception to this was ALL, where one-year 
relative survival for emergency presentations was similar to that from all other routes. 
For some acute haematological malignancies emergency presentation may be the 
most appropriate route to diagnosis1.  
 c) Evidence review and quality grading 
Searches were carried out in Medline. Premedline, Embase, Cochrane, LibraryWeb 
of Science (SCI & SSCI) and ISI Proceedings, HMIC, PscyInfo, CINAHL, Joanna 
Briggs Institute EBP database, OpenGrey, HMRN (Haematological Malignancy 
Research Network) and British Committee for Standards in Haematology from 
January 2000 until April 2015. Results of the searches are detailed in Figure 1. In 
total 19 studies were included in the review (table 1)5-7, 9-24. 
Figure 1: Search Results 
 
The evidence was considered to be of low quality overall as all the identified studies 
were retrospective case series and none of them directly compared integrated 
diagnostic services with other forms of diagnostic service. There was a high risk of 
bias based on the potential lack of blinding and the possibility of selection bias. 
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One study (Engel-Nitz et al, 2014) however compared diagnostic outcomes between 
specialist haematology laboratories and other commercial laboratories, reporting that 
patients in the specialist laboratory cohort were more likely to undergo more complex 
diagnostic testing with 26% of patients undergoing molecular diagnostics compared 
with 9.3% in community based hospital laboratories. Patients in the specialist 
laboratory cohort were 23% more likely to reach a final diagnosis within a 30 day 
testing period when compared with community based hospital laboratories. 
 
Table 1: Studies included in Evidence Review 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
1 Bowen et al 
(2014) 
Retrospective 
Study 
To determine the rate of 
revised diagnosis and 
subsequent impact on 
therapy following a second 
review 
N=1010 
Second Review 
Diagnosis 
Primary 
referral 
diagnosis 
Diagnostic Discrepancies 
2 Chang et al 
(2014) 
Retrospective 
Study 
To review the final 
diagnoses made by 
general pathologists and 
analyse the discrepancies 
between referral and 
review diagnosis 
N=395 
Expert Review Initial 
Diagnosis 
Diagnostic Discrepancies 
3 Engel Nitz et 
al (2014) 
Retrospective 
Study 
 
Laboratory 
To compare diagnostic 
changes, patterns of 
additional testing, 
treatment decisions and 
health care costs for 
patients with suspected 
haematological 
malignancies/conditions 
whose diagnostic tests 
were managed by specialty 
haematology laboratories 
and other commercial 
laboratories. 
N=24,664 patients  
 
Genoptix N=1,387 
Large Labs N=4,162 
Other Controls 
(community hospital 
labs) N=19,115 
 
Initial interim 
diagnosis 
Final 
Diagnosis 
Diagnostic Uncertainty 
Stability of Diagnosis 
4 Gundlapalli et 
al (2009) 
Survey To address the hypotheses 
that clinical providers 
perceive composite 
laboratory reports to be 
important for the care of 
complex patients and that 
such reports can be 
generated using laboratory 
informatics methods 
N=10 clinical staff 
Survery and 
interview 
None 
End user survey opinions 
 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
5 Herrera et al 
(2014) 
Retrospective 
Study 
To evaluate the rate of 
diagnostic concordance 
between referring centre 
diagnoses and expert 
haematology review for 4 
subtypes of T-cell 
lymphoma 
N=89 
Review of 
primary 
diagnosis at an 
NCCN centrte 
Primary 
diagnosis at a 
referring 
centre 
Concordance 
6 Irving et al 
(2009) 
Report To show that the 
standardised protocol has 
high sensitivity and 
technical applicability, has 
good concordance with the 
gold standard molecular 
based analysis and is 
highly reproducible 
between laboratories 
across different instrument 
platforms. 
No details 
Standardised 
protocol for flow 
cytometry 
Gold standard 
molecular 
technique 
Internal and external quality 
assurance testing of flow 
minimal residue disease 
Sensitivity and varibility of the 
standardised method 
Applicability of the 
standardised method in 
prospective samples 
Comparison of minimal 
residual disease as measured 
by PCR and by flow cytometry 
7 LaCasce et al 
(2005) 
Retrospective 
Study To determine the rate of 
discordance for 5 common 
B-cell NHL diagnoses in 
five tertiary centres 
participating in a large 
national lymphoma 
database 
The determine whether 
additional information was 
obtained at the National 
Comprehensive Cancer 
Network (NCCN) centre 
To estimate the likely 
impact of a change in 
diagnosis on treatment 
N=928 
Pathologic 
diagnosis from 
the referral 
centre was 
compared with 
the final WHO 
diagnosis at the 
NCCN centres  
 
Etiology of the 
discordance was 
investigated 
along with the 
potential impact 
on treatment.  
No Details 
Pathologic Discordance 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
 
A random 
sample of 
concordant 
cases (10%) 
were also 
reviewed 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
8 Lester et al 
(2003) 
Retospective 
Study 
To establish the impact of 
the All Wales Lymphoma 
Panel review on clinical 
management decisions 
N=99 
Cases submitted 
for central 
review 
Actual 
management 
plan received 
by the patient 
Change in management 
9 Matasar et al 
(2012) 
Retrospective 
Study 
 
Laboratory Setting 
To test the hypothesis that 
increased familiarity with 
the WHO classification of 
haematological 
malignancies is associated 
with a change in frequency 
of major diagnostic revision 
at pathology review. 
N=719 
Diagnosis and 
review in 2001 
using the WHO 
classification of 
haematological 
malignancies 
Diagnosis and 
review in 2006 
using the 
WHO 
classification 
of 
haematologica
l malignancies 
Agreement between the 
submitted and review 
diagnosis (most recent 
diagnosis was considered 
the submitted diagnosis) 
Factors associated with the 
rate of major diagnostic 
revisions  
 
10 Norbert-
Dworzak et al 
(2008) 
Prospective 
Review 
To investigate whether flow 
cytometric assessment of 
minimal residual disease 
can be reliably 
standardised for multi-
centric application 
N=413 patients with 
acute lymphoblastic 
leukaemia (Centre 
1=110, Centre 2=88, 
Centre 3=61, Centre 
4=154) 
 
N=395 patients with 
blood and bone marrow 
samples received at 
diagnosis and from 
follow-up during 
induction treatment: PB 
at day 8, 15, 22, and 
33; BM at day 15, 33 
and 78). 
 
Flow Cytometry 
according to a 
standard 
protocol 
Results from 
each centre 
following 
standard 
protocol 
Qualitative Concordance of 
Analyses of Exchanged List-
Mode Data 
Quantitative Concordance of 
Analyses of Exchanged List-
Mode Data 
Concordance of Risk 
Estimates upon Analyses of 
Exchanged List-Mode Data 
Reproducibility in Inter-
Laboratory Sample 
Exchange 
Agreement of MRD Results 
from independent patient 
cohorts 
 
11 Norgaard et 
al (2005) 
Retrospective 
Study 
To examine the data 
quality and quantifying the 
impact of any 
misclassification of the 
N=1159 
Danish Cancer 
Registry (DCR) 
North Jutland 
Hospital 
Discharge 
Degree of completeness 
Positive Predictive Value 
Survival 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
diagnoses on the survival 
estimates 
Registry 
12 Proctor et al 
(2011) 
Retrospective 
Study 
A large scale assessment 
of expert central review in 
a UK regional cancer 
network and the impact of 
discordant diagnoses on 
patient management as 
well as the financial and 
educational implications of 
providing a centralised 
service. 
N=1949 
Expert Review Initial 
Diagnosis 
Concordance 
13 Rane et al 
(2014) 
Retrospective 
Study 
To evaluate the ability and 
interobserver variability of 
pathologists with varying 
levels of experience and 
with an interest in 
lymphomas to diagnose 
Burkitt Lymphoma in a 
resource limited set up. 
N=25 
Consensus 
Diagnosis 
Initial 
Independent 
Assessment 
Initial Independent 
Assessment 
Interobserver variation in 
morphological features 
Parameters used to 
differentiate between classic 
CL, atypical BL and B-cell 
lymphoma intermediate 
between DLBL and Burkitt 
lymphoma.  
Consensus Diagnosis 
Concordance with 
consensus diagnosis 
Effect of tissue fixation, age 
group and provision of 
additional information on 
revision of diagnoses  
Accuracy of pathologist¶s 
Sensitivity and Specificity to 
diagnose Burkitt Lymphoma 
 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
14 Siebert et al 
(2001) 
Retropsective 
Study 
To compare diagnoses 
made at a community and 
an academic centre to 
evaluate the reproducibility 
of the revised European-
American Classification 
N=188 
Review of 
community 
hospital 
assessments at 
an academic 
centre 
lymphoid 
neoplasms 
subtyped 
according to 
revised 
European-
American 
classification 
criteria at a 
community 
hospital 
Concordance 
15 Stevens et al 
(2012) 
Retrospective 
Study 
To observe concordance 
and discrepancies between 
local findings and the 
specialist opinion. 
N=125 
Central Review Regional/Com
munity 
Hospital 
Review 
Pathology 
Staging 
Therapy 
16 Strobbe et al 
(2014) 
Retrospective 
Study 
To investigate whether 
implementation of an 
expert panel led to better 
quality of initial diagnoses 
by comparing the rate of 
discordant diagnoses after 
the panel was established 
compared with discordance 
rate 5 years later 
 
To evaluate whether 
lymphoma types with high 
discordance rate could be 
identified 
N=161 referred to the 
expert panel 
N=183 reviewed at a 
later date 
Expert Panel 
review 
Initial 
Diagnosis 
Discordance rate in 2000-
2001  
Discordance rate in 2005-
2006 
 
17 Van Blerk et 
al (2003) 
Retrospective 
Study 
To report first experiences 
from Belgian national 
external quality 
assessment scheme 
(EQAS) 
N=17 
External quality 
assessment 
review 
N/A 
Stability 
Intralaboratory reproducibility 
Homogeneity 
Interlaboratory reproducibility  
Single vs. Dual Platform 
Study Study 
Type/Setting 
Aim Population  Intervention Comparison Outcomes 
Influence of Gating strategy 
CD4+,CD3+ and CD8+CD3+ 
cells versus total CD4 and 
CD8 cells 
Abnormal Samples 
18 Van de 
Schans et al 
(2013) 
Retrospective 
Study 
To evaluate the value of an 
expert pathology panel and 
report discordance rates 
between the diagnosis of 
initial pathologists and the 
expert panel and the effect 
on survival 
N=344 
Expert review of 
diagnosis 
Initial 
Diagnosis 
Discordance Rate 
19 Zhang et al 
(2007) 
Retrospective 
Study 
To compare similarities 
and differences in results 
from participating 
laboratories and to identify 
variables which could 
potentially affect test 
results to discern variables 
important in test 
standardisation 
N=38 laboratories Quantitative 
testing for BCR-
ABL1 
Results from 
different 
participating 
laboratories 
Test accuracy at different 
dilutions 
 
 
d) Cost Effectiveness Analysis 
 
No previous studies of cost effectiveness were identified as part of the evidence 
review. An economic model was therefore developed to inform the guideline. The 
economic model considered the cost effectiveness of two overall models of 
haematological malignancy diagnostic service delivery: (a) local reporting of 
diagnostic results with a proportion of tests being referred to SIHMDS for review and 
(b) referring all samples immediately to SIHMDS for suspected haematological 
malignancies. When considering the SIHMDS itself, two comparative configurations 
of SIHMDS were considered: (a) networked and (b) co-located. Health outcomes 
were calculated as lifetime Quality Adjusted Life Years (QALYs) and all costs to the 
NHS and Personal Social Services (PSS) were considered. Costs were 
predominantly taken from accounting data of one networked and one co-located 
SIHMDS. Health outcomes were based on the Guideline Committee¶V assumptions 
on the impact of misdiagnoses informed by clinical evidence of treatment for 
haematological malignancies. In the absence of strong evidence differentiating the 
two SIHMDS approaches their health outcomes were assumed identical. A range of 
sensitivity analyses were performed to test differing assumptions and to assess the 
robustness of and uncertainty around outcomes. 
 
In the model, both approaches of SIHMDS had a lower cost per diagnosis and higher 
QALYs per patient compared to local reporting with subsequent referral of a 
proportion of cases to the SIHMDS. When comparing SIHMDS structure, a co-
located approach was estimated to be £19 cheaper per diagnosis compared with a 
networked approach, although this was not robust during sensitivity analysis.  
 
Change in staffing, capital and set-up costs were not considered as part of the 
economic modelling with this varying widely across England. It was acknowledged 
that there may be a significant initial resource impact on some centres around 
obtaining laboratory accommodation, implementation of integrated IT systems and 
the appointment of dedicated SIHMDS staff. 
 
There was no evidence to directly compare outcomes from co-located and 
networked haematology diagnostic services and strong conclusions regarding the 
preferred configuration of SIHMDS could not be drawn solely from the results of the 
economic model. One study11 reported significantly better clinical outcomes for a 
specialist haematology diagnostic laboratory, but it was unclear from the information 
provided, whether this study directly compared co-located and networked services. 
Communication with the author of the study added extra information about the 
comparisons made and the Guideline Committee debated whether this warranted a 
recommendation for a co-located diagnostic service to optimise integration of the 
increasingly complex range of tests involved in the diagnosis of haematological 
malignancies required to fulfil WHO specifications. There was consensus in the 
Guideline Committee that a co-located service was the optimal approach and that, 
because it allowed more effective processes and procedures to be put in place, 
better communication between laboratory personnel and better quality control, it 
should be recommended, despite the lack of strong evidence.  
The Guideline Committee agreed that there were a number of geographical and 
infrastructural barriers to establishing a co-located service and that the priority in any 
diagnostic service was delivering a high quality service that produced timely 
integrated reports. Although this was likely to be best met through a service with all 
the component parts located on a single site, this would not always be feasible and 
so a networked service might be a more appropriate option for certain parts of 
England. To clarify the key service requirements, the Guideline Committee 
developed a set of consensus-based recommendations outlining the key 
organisational, structural and managerial parameters, which should be fulfilled by 
any SIHMDS, whether co-located or networked. No specific evidence was identified 
about paediatric diagnosis but the Guideline Committee considered that diagnosis of 
paediatric patients would follow the same diagnostic pathways as that of adult 
patients and so the recommendations should cover all age groups.  
 
Recommendations 
The following is a list of the new, updated recommendations for 2016. For all 
recommendations, the quality of the evidence was considered to be low.  
The Guideline Committee considered that recommendations are most likely to be 
achieved if the component parts of the SIHMDS are located at a single site. 
All SIHMDS should: 
x have clearly defined organisational structures 
x have a formally appointed SIHMDS director who is responsible for the 
operation of the service, including the design of the diagnostic pathway, 
resource use and reporting standards  
x have a single quality management system 
x be formally accredited as a SIHMDS by a recognised independent 
organisation 
x be managed by a single trust/organisation  
x assess the clinical benefit and the financial and resource impact of new 
diagnostic and therapeutic technologies before introducing them 
x have a central reception point for all specimens  
x have a full range of age-appropriate specialist haematology and 
haematopathology input for diagnosis and the authorisation of integrated 
reports 
x have a full range of protocols covering specimen handling, diagnostic 
pathways and compilation of integrated reports  
x ensure that their location, organisation, infrastructure and culture allow 
effective day to day and ad-hoc communication for rapid resolution of 
diagnostic uncertainty and accurate diagnosis 
x have clear and reliable systems for communicating with relevant healthcare 
professionals outside the SIHMDS 
x produce integrated reports that include all information needed for disease 
management, and share these with the relevant multi-disciplinary team.  
x report diagnoses sub-typed by the current WHO classification. 
All SIHMDS should have a predefined diagnostic pathway that is followed for each 
specimen type or clinical problem. The pathway should ensure that:  
x the most appropriate diagnostic platforms are selected for a particular clinical 
situation to avoid unnecessary duplication 
x tests for each specimen are used to provide maximum levels of internal cross-
validation, using the current WHO principle of multi-parameter disease 
definitions 
x there is a robust process for report validation, including double reporting.  
All SIHMDS should have an IT system that allows: 
x specimen booking and registration at source 
x input and update of clinical information 
x integrated reporting 
x two-way communication between SIHMDS and healthcare professionals 
using the SIHMDS.  
The SIHMDS director should be responsible for the overall quality management 
system, including: 
x laboratory processes and the quality of diagnostic reporting  
x ongoing assessment of staff competencies 
x training provision 
x communication within the SIHMDS and with relevant healthcare professionals 
x audit and quality assurance 
x research and development.  
 
If an urgent treatment decision is not needed, local diagnostic laboratories should 
send all specimens (including lymph node and other tissue material) directly to a 
SIHMDS without any local diagnostic workup: 
 
x as soon as a haematological malignancy is suspected 
x during active investigation of a suspected haematological malignancy 
x if patients with an established or previous malignancy have suspected relapse 
or disease progression. 
 
If an urgent treatment decision is needed and local diagnostic workup will not reduce 
the speed or quality of the SIHMDS assessment and integrated reporting, local 
diagnostic laboratories should process and report on blood film, bone marrow 
aspirate and cerebrospinal fluid cytology specimens. 
SIHMDS should release individual laboratory reports before the integrated report is 
produced, if there is an urgent clinical need. 
SIHMDS should be responsible for specimens that are sent to external labs and 
should integrate the results into the relevant report (unless there are exceptional 
arrangements in place for clinical trials). 
Disease monitoring 
When flow cytometry, molecular diagnostics or cytogenetics are needed for disease 
monitoring, local diagnostic laboratories should send all relevant specimens directly 
to a SIHMDS without any local diagnostic workup.  
Discussion 
The concept of SIHMDS is not new and was a result of recognition that 
haematological malignancy diagnosis is increasingly complex and dependent on new 
sophisticated laboratory technology. Separate laboratory reporting and reliance on 
clinicians to interpret and synthesise each result and stay up-to-date with ongoing 
revisions in classification is likely to compromise diagnostic quality despite the dual 
clinical and laboratory training and certification achieved by the majority of 
haematologists in the UK. This is due to the complexity of current diagnostic 
methods and the requirement to internally validate and cross-check information, at 
source, in order to preventing reporting of erroneous results.  
 
From the late 1990s, some UK centres adopted an integrated approach which was 
incorporated into the NICE IOG in 2003 and subsequent cancer peer review 
standards. Despite this, many services did not progress integrated reporting beyond 
an elementary stage, consistent with local reporting. Additionally, although modern 
diagnostic technology and classifications are relevant to all age groups, patients 
under 16 had a different standard of care to those over 16. Others developed 
different models; some using co-located facilities and others using networked but 
geographically distinct laboratory facilities to produce integrated reports. As there 
were pros and cons associated with both models, the Guideline Committee 
considered an economic analysis as well as clinically important aspects in 
formulating their recommendations.  
 
A fully co-located service is a logical and convenient means of delivering SIHMDS. It 
permits consolidation of expert diagnostic staff and expensive technologies and is 
more likely to result in reduced turn-around times, improved diagnostic accuracy, 
reduced need for repeat sampling and greater cost efficiency. This should in turn 
lead to more effective treatment and less anxiety for patients. However, there are a 
number of potential barriers to setting up co-located SIHMDS services, in particular 
the need to restructure services. Some laboratories such as histopathology and 
molecular genetics have a broad remit across all cancer and non-cancer specialities, 
which prevents separation of their haematological services into a co-located 
SIHMDS. In rural regions, geographically isolated and disparate units with relatively 
small populations may find this restructuring a challenge with particular regard to 
recruitment, job satisfaction and ability to effectively communicate and attend MDT 
meetings: although modern telecommunications and developing digitalization could 
mitigate some aspects. 
Balancing potential benefits against challenges around service reconfiguration, staff 
satisfaction, haematology training provision and recruitment, there was agreement 
that these recommendations were in the best interests of the service and the 
patients. 
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